148 related articles for article (PubMed ID: 38305004)
1. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q;
BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080
[TBL] [Abstract][Full Text] [Related]
3. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
5. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
6. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
7. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
Lammers PE; Dank M; Masetti R; Abbas R; Hilton F; Coppola J; Jacobs I
Br J Cancer; 2018 Aug; 119(3):266-273. PubMed ID: 30002437
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
[TBL] [Abstract][Full Text] [Related]
10. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
AbdulHameed Saeed V; Mohammed NAK
Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
[TBL] [Abstract][Full Text] [Related]
11. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
12. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
13. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
Muñoz C; Tai X; Arias J; Eisen A; Chaudhry M; Gavura S; Chan KKW
Curr Oncol; 2024 Mar; 31(3):1633-1644. PubMed ID: 38534957
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract][Full Text] [Related]
16. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
17. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
19. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of biosimilar trastuzumab MYL-1401O in HER2-positive breast cancer.
Eser K; Sezer E; Erçolak V; İnal A
Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
